Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07453394) titled 'QLS5132 Combination Therapy in Advanced Solid Tumors' on March 1.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Qilu Pharmaceutical Co., Ltd.
Condition:
Gastric Cancer (GC)
Non-small Cell Lung Cancer (NSCLC)
Endometrial Cancer
Advanced Solid Tumors
Ovarian Cancer
Intervention:
Drug: QLS5132
Bevacizumab
Drug: QLS5132
Platinum
Bevacizumab
Drug: QLS5132
Olaparib
Bevacizumab
Drug: QLS5132
QL1706
QL2107
Drug: QLS5132
QL1706
QL2107
Carboplatin
Cisplatin
Recruitment Status: Not rec...